TABLE 3.
Results of verification study
| Antimicrobiala | No. of strains with log2 difference from reference MICb |
% agreement (95% CI) |
||||||
|---|---|---|---|---|---|---|---|---|
| −2 | −1 | 0 | 1 | 2 | Overall essential | Evaluable essential | Categorical | |
| AMP | 0 | 2 | 10 | 19 | 3 | 95.0 (87.8–98.0) | 91.2 (77.0–97.0) | 95 (87.8–98.0) |
| CFZ | 0 | 9 | 34 | 5 | 0 | 100 (95.3–100.0) | 100 (92.6–100) | 92.3 (84.2–96.4) |
| CIP | 0 | 2 | 12 | 10 | 0 | 94.9 (87.5–97.9) | 100 (86.2–100) | 98.7 (93.1–99.8) |
| CL | 1 | 3 | 17 | 7 | 2 | 73.7 (63.2–82.1) | 90 (73.6–96.4) | 100 (95.4–100) |
| GEN | 1 | 12 | 36 | 22 | 6 | 90.0 (81.5–94.8) | 91 (82.4–95.5) | 97.5 (91.3–99.3) |
| MEM | 0 | 4 | 32 | 17 | 1 | 96.3 (89.5–98.7) | 98.1 (90.2–99.7) | 97.5 (91.3–99.3) |
| TET | 1 | 5 | 41 | 17 | 5 | 86.3 (77.0–92.1) | 91.3 (82.3–96.0) | 95 (87.8–98.0) |
| Total n (% or %, 95% CI) | 3 (0.9) | 37 (11.0) | 182 (54.2) | 97 (28.9) | 17 (5.0) | 505 (91.0, 88.1–93.0) | 315 (94.0, 91.0–96.1) | 536 (96.6, 94.7–97.8) |
a
AMP, ampicillin; CFZ, cefazolin; CIP, ciprofloxacin; CL, colistin; GEN, gentamicin; MEM, meropenem; TET, tetracycline.
b
Only evaluable comparisons for which both DDM and BMD measurements were within the dilution ranges tested were included.